Le Lézard
Classified in: Covid-19 virus
Subject: IPO

Pegasus Development Major Upcoming IPO in 2021


Pegasus Development, Inc. is pleased to announce that the first important step for the planned IPO / Listing in 2021 has been taken. The application with the SEC / EDGAR - Securities and Exchange Commission in the USA has been approved and the registration in the IPO register has taken place. Planned IPO date is June 2021, the main venues are Frankfurt and New York stock exchanges. With multiple rounds of financing, investors will have the opportunity to invest in a growing company and receive equity or a portion of the company in return.

The default-free bond repayments and the high sales figures of the past years have enormously strengthened the confidence of the investors in Pegasus Development and give the internationally positioned company the decisive psychological advantage for the IPO.

Above all, the growth in operating business despite COVID-19 is the decisive signal effect for all shareholders. Important here are the dialogues with major American investors who would like to accompany this lucrative IPO. At an early stage it can be seen here that good business is also being weathered in the environment and many parties would like to participate on this IPO.

Pre-IPO shares with right of first refusal are usually traded exclusively among financial institutions and major investors and are not accessible to private investors. However, Pegasus Development has announced for its existing investors that a contingent of forehanded shares will be made available to thank them for their trust over the last 20 years and give them the opportunity to participate in the game of the big ones without having to provide millions of dollars.

All in all, we can look forward to a strong performance and are eagerly awaiting further events.

Language: English
Company: Pegasus Development GmbH
Friedrich-Ebert-Anlage 36
60325 Frankfurt am Main
Germany
Internet: www.pegasusdevelopment.de

 


These press releases may also interest you

at 08:35
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...

at 07:05
Mirum Pharmaceuticals, Inc. today announced data presented during the 56th European Society for Paediatric, Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Annual Meeting which took place this week in Milan, Italy. Data from LIVMARLI®...

17 mai 2024
Federal, provincial and territorial (FPT) ministers responsible for culture and heritage held their annual meeting in Whitehorse, Yukon, on May 15?17, 2024, to discuss priority topics, share information and exchange best practices on current issues...

17 mai 2024
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of QuidelOrtho Corporation between February 18, 2022 and April 1, 2024, both dates inclusive (the "Class Period") of the important June 11, 2024 lead...

17 mai 2024
The TCW Group, a leading global asset management firm, today announced that, effective May 30, 2024, the listing exchange for shares of each of the following series (each, an "ETF" and, collectively, the "ETFs") of TCW ETF Trust (the "Trust") will be...

17 mai 2024
BioLineRx Ltd. ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has received a notification letter from the Nasdaq Stock Market LLC...



News published on and distributed by: